Defects in alternative splicing are frequently found in human tumors and result either from
mutations in splicing‐regulatory elements of specific cancer genes or from changes in the …

Cancer stem cells (CSC) are a distinct subpopulation within a tumor. They are able to self-
renew and differentiate and possess a high capability to repair DNA damage, exhibit low …

Abstract Development of novel strategies to overcome chemoresistance is central goal in
ovarian cancer research. Natural history of the cancer development and progression is …

Objective The majority of genes are alternatively spliced and growing evidence suggests
that alternative splicing is modified in cancer and is associated with cancer progression …

Cancer stem cells (CSCs) may contribute to an increased risk of recurrence in ovarian
cancer (OC). Further research is needed to identify associations between CSC markers and …

Cancer-associated mesothelial cells (CAMCs) in the tumor microenvironment are thought to
promote growth and immune evasion. We find that, in mouse and human ovarian tumors …

Epithelial splicing regulatory protein 1 (ESRP1) and 2 (ESRP2), epithelial cell-specific
regulators of alternative splicing, are downregulated during the epithelial–mesenchymal …

Abstract Cluster of differentiation 44 (CD44), a marker for cancer stem cells, has been
reported to be associated with poor prognosis in non‑small cell lung cancer (NSCLC), but its …

Cancer stem-like cells (CSLCs) are defined as cancer cells with stem cell characteristics.
Although CSLCs constitute no more than a few percent of the tumor mass, they play …

Lung cancer, the second leading cause of cancer-related mortality and incidence globally,
presents a formidable challenge with an estimated 238,340 new cases and 127,070 deaths …